Innovus Pharmaceuticals, Inc.
http://www.innovuspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Innovus Pharmaceuticals, Inc.
Step Pharma Aims To Become CTP Synthase 1 Leader, Starting With Aggressive Lymphoma
Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.
Finance Watch: Morningside Launches Adiso With More Than $60m In Early Funding
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
Step Pharma Set To Leap Into Clinic With CTPS1 Inhibitor
After a fresh cash injection, Step is ready to take STP938 for the treatment of T-cell blood cancers into Phase I trials in February.
Patience Is A Virtue For French VC Kurma
Thierry Laugel, managing partner of the Paris-based financiers, tells Scrip about the virtues of its 'company creation model,' giving innovative ideas time to mature rather than rushing to the market.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Beyond Human, LLC
- FasTrack Pharmaceuticals, Inc.
- Novalere
- Semprae.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice